on no account [0.05:<2000> <25,000 50% A repeat course of CeeNU should not be given until circulating blood elements have returned to acceptable levels (platelets above 100,000/mm 3 ; leukocytes above 4000/mm 3 ), and this is usually in 6 weeks. Adequate number of neutrophils should be present on a peripheral blood smear. Blood counts should be monitored weekly and repeat courses should not be given before 6 weeks because the hematologic toxicity is delayed and cumulative. How is CeeNU Supplied CeeNU (lomustine) Capsules are available in individual bottles of 20 capsules each. NDC 0015-3032-20 100 mg capsules (Green/Green) NDC 0015-3031-20 40 mg capsules (White/Green) NDC 0015-3030-20 10 mg capsules (White/White) Stability CeeNU Capsules are stable for the lot life indicated on package labeling when stored in well-closed containers at 25 C (77 F); excursions permitted to 15 C 30 C (59 F 86 F) [see USP Controlled Room Temperature]. Avoid excessive heat (over 40 C, 104 F). Directions to the Pharmacist Confirm the total dose prescribed by the physician can be obtained by determining the appropriate combination of capsule strengths. Only the appropriate number of CeeNU capsules required for the administration of a single dose should be dispensed. In order to provide the proper dose of CeeNU, patients should be aware that the prescribed dose may be made up of 2 or more different strengths and colors of capsules and that each strength must be dispensed separately. Inform patients that CeeNU is taken as a single oral dose and will not be repeated for at least 6 weeks. Daily use of the recommended dose may lead to toxicities and fatal outcomes. Caution should be exercised when handling CeeNU Capsules. Procedures for proper handling and disposal of anticancer drugs should be utilized. Several guidelines on this subject have been published. 1-4 To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing CeeNU Capsules. CeeNU Capsules should not be broken. Personnel should avoid exposure to broken capsules. If contact occurs, wash immediately and thoroughly. More information is available in the references listed below. REFERENCES NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006;63:1172 1193. Polovich M, White JM, Kelleher LO, eds. 2005. Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society. Manufactured for: Bristol-Myers Squibb Company Princeton, NJ 08543 USA Made in Italy Rev November 2012 ----------------------------------------- REPRESENTATIVE PACKAGING See How Supplied section for a complete list of available packages of CeeNU Capsules. NDC 0015-3032-20 20 CAPSULES CeeNU (lomustine) Capsules Rx only 100 mg per capsule Caution: DO NOT DISPENSE ENTIRE CONTAINER. Dispense only enough capsules for one dose. NDC 0015-3031-20 20 CAPSULES CeeNU (lomustine) Capsules Rx only 40 mg per capsule Caution: DO NOT DISPENSE ENTIRE CONTAINER. Dispense only enough capsules for one dose. NDC 0015-3030-20 20 CAPSULES CeeNU (lomustine) Capsules Rx only 10 mg per capsule Caution: DO NOT DISPENSE ENTIRE CONTAINER. Dispense only enough capsules for one dose. CeeNU lomustine capsule, gelatin coated Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0015-3032 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength lomustine (lomustine) lomustine 100 mg Inactive Ingredients Ingredient Name Strength magnesium stearate mannitol Product Characteristics Color GREEN Score no score Shape CAPSULE Size 19mm Flavor Imprint Code Bristol;3032;100;mg Contains Packaging # Item Code Package Description 1 NDC:0015-3032-20 1 BOTTLE in 1 CARTON 1 20 CAPSULE, GELATIN COATED in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA017588 12/15/2008 06/30/2014 CeeNU lomustine capsule, gelatin coated Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0015-3031 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength lomustine (lomustine) lomustine 40 mg Inactive Ingredients Ingredient Name Strength magnesium stearate mannitol Product Characteristics Color GREEN, WHITE Score no score Shape CAPSULE Size 18mm Flavor Imprint Code Bristol;3031;40;mg Contains Packaging # Item Code Package Description 1 NDC:0015-3031-20 1 BOTTLE in 1 CARTON 1 20 CAPSULE, GELATIN COATED in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA017588 12/15/2008 04/15/2016 CeeNU lomustine capsule, gelatin coated Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0015-3030 Route of Administration ORAL DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength lomustine (lomustine) lomustine 10 mg Inactive Ingredients Ingredient Name Strength magnesium stearate mannitol Product Characteristics Color WHITE Score no score Shape CAPSULE Size 16mm Flavor Imprint Code Bristol;3030;10;mg Contains Packaging # Item Code Package Description 1 NDC:0015-3030-20 1 BOTTLE in 1 CARTON 1 20 CAPSULE, GELATIN COATED in 1 BOTTLE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA017588 12/15/2008 04/15/2016 Labeler - E.R. Squibb & Sons, L.L.C. (968242821) Revised: 11/2012 E.R. Squibb & Sons, L.L.C. Next Interactions Print this page Add to My Med List More about CeeNU (lomustine) Side Effects During Pregnancy Dosage Information Drug Images Drug Interactions Support Group 0 Reviews Add your own review/rating Drug class: alkylating agents Consumer resources Ceenu (Advanced Reading) Professional resources Lomustine (AHFS Monograph) Lomustine (FDA) Other brands: Gleostine , CCNSB Capsules Related treatment guides Anaplastic Oligodendroglioma Brain Tumor Hodgkin's Lymphoma> ] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only D Pregnancy Category Positive evidence of risk N/A CSA Schedule Not a controlled drug Manufacturer Bristol-Myers Squibb Company Drug Class Alkylating agents Related Drugs alkylating agents carboplatin , cisplatin , cyclophosphamide , oxaliplatin , Cytoxan , Temodar Brain Tumor cisplatin , lomustine , carmustine , Gliadel , Platinol , Gleostine , BiCNU , Platinol-AQ , More... Hodgkin's Lymphoma Opdivo , Keytruda , cyclophosphamide , nivolumab , Cytoxan , etoposide , Adriamycin , doxorubicin , More... Anaplastic Oligodendroglioma vincristine , lomustine , Gleostine , Matulane , procarbazine , Oncovin , More... CeeNU Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! CeeNU Images CeeNU 10 mg (BRISTOL 3030 10 mg) View all images for reinforcing
reasonably priced CeeNU even if
EmoticonEmoticon